O	0	1	[
O	1	11	Comparison
O	12	19	between
B-intervention	20	32	intratumoral
O	33	36	and
B-control	37	48	peritumoral
I-control	49	58	injection
I-control	59	61	of
I-control	62	73	radiotracer
O	74	77	for
O	78	86	locating
O	87	90	and
O	91	100	biopsying
O	101	104	the
O	105	113	sentinel
O	114	119	lymph
O	120	124	node
O	125	127	in
O	128	139	nonpalpable
O	140	146	breast
O	147	153	cancer
O	153	154	]
O	154	155	.

O	156	158	To
O	159	168	determine
O	169	176	whether
O	177	182	there
O	183	186	are
O	187	198	differences
O	199	201	in
O	202	205	the
O	206	215	technical
O	216	224	efficacy
O	225	227	in
O	228	237	detecting
O	238	241	and
O	242	251	biopsying
O	252	255	the
O	256	264	sentinel
O	265	269	node
O	270	275	after
O	276	288	intratumoral
O	289	291	or
O	292	303	peritumoral
O	304	318	administration
O	319	321	of
O	322	325	the
O	326	337	radiotracer
O	338	340	in
O	341	349	patients
O	350	354	with
O	355	366	nonpalpable
O	367	372	early
O	372	373	-
O	373	378	stage
O	379	385	breast
O	386	392	cancer
O	392	393	.

O	394	398	This
O	399	410	prospective
O	410	411	,
O	412	422	randomized
O	423	428	study
O	429	437	included
B-total-participants	438	440	80
B-eligibility	441	449	patients
I-eligibility	450	454	with
I-eligibility	455	466	nonpalpable
I-eligibility	467	473	breast
I-eligibility	474	480	cancer
I-eligibility	481	488	without
I-eligibility	489	497	axillary
I-eligibility	498	510	adenopathies
I-eligibility	511	514	who
I-eligibility	515	519	were
I-eligibility	520	529	scheduled
I-eligibility	530	533	for
I-eligibility	534	541	primary
I-eligibility	542	550	surgical
I-eligibility	551	560	treatment
O	560	561	.

O	562	570	Patients
O	571	575	were
O	576	586	randomized
O	587	589	to
O	590	593	one
O	594	596	of
O	597	600	two
O	601	607	groups
O	607	608	:
O	609	612	the
O	613	618	INTRA
O	619	624	group
O	625	626	(
O	626	638	intratumoral
O	639	650	radiotracer
O	651	665	administration
O	665	666	,
O	667	668	n
O	668	669	=
B-intervention-participants	669	671	35
O	671	672	)
O	673	675	or
O	676	679	the
O	680	684	PERI
O	685	690	group
O	691	692	(
O	692	703	peritumoral
O	704	715	radiotracer
O	716	730	administration
O	730	731	,
O	732	733	n
O	733	734	=
B-control-participants	734	736	45
O	736	737	)
O	737	738	.

O	739	747	Patients
O	748	752	with
O	753	763	suspicious
O	764	772	axillary
O	773	778	lymph
O	779	784	nodes
O	785	787	at
O	788	796	clinical
O	797	799	or
O	800	816	ultrasonographic
O	817	828	examination
O	829	833	that
O	834	837	had
O	838	846	positive
O	847	854	results
O	855	860	after
O	861	865	fine
O	865	866	-
O	866	872	needle
O	873	883	aspiration
O	884	892	cytology
O	893	897	were
O	898	906	excluded
O	906	907	.

O	908	911	The
B-outcome	912	917	rates
I-outcome	918	920	of
I-outcome	921	929	sentinel
I-outcome	930	934	node
I-outcome	935	944	detection
O	945	949	were
B-iv-bin-percent	950	952	97
I-iv-bin-percent	952	953	.
I-iv-bin-percent	953	954	1
I-iv-bin-percent	954	955	%
O	956	957	(
B-iv-bin-abs	957	959	34
O	959	960	/
B-intervention-participants	960	962	35
O	962	963	)
O	964	967	for
O	968	980	intratumoral
O	981	990	injection
O	991	994	and
B-cv-bin-percent	995	997	84
I-cv-bin-percent	997	998	.
I-cv-bin-percent	998	999	4
I-cv-bin-percent	999	1000	%
O	1001	1002	(
B-cv-bin-abs	1002	1004	38
O	1004	1005	/
B-control-participants	1005	1007	45
O	1007	1008	)
O	1009	1012	for
O	1013	1024	peritumoral
O	1025	1034	injection
O	1034	1035	.

B-outcome	1036	1047	Radiotracer
I-outcome	1048	1057	migration
I-outcome	1058	1065	failure
O	1066	1074	occurred
O	1075	1077	in
O	1078	1079	8
O	1080	1085	cases
O	1086	1087	(
B-iv-bin-abs	1087	1090	one
O	1091	1093	in
O	1094	1097	the
O	1098	1103	INTRA
O	1104	1109	group
O	1110	1113	and
B-cv-bin-abs	1114	1115	7
O	1116	1118	in
O	1119	1122	the
O	1123	1127	PERI
O	1128	1133	group
O	1133	1134	)
O	1134	1135	.

O	1136	1139	The
B-outcome	1140	1148	sentinel
I-outcome	1149	1153	node
I-outcome	1154	1157	was
I-outcome	1158	1166	detected
I-outcome	1167	1169	in
I-outcome	1170	1172	an
I-outcome	1173	1178	extra
I-outcome	1178	1179	-
I-outcome	1179	1187	axillary
I-outcome	1188	1196	location
O	1197	1199	in
O	1200	1202	21
O	1202	1203	.
O	1203	1204	9
O	1204	1205	%
O	1206	1208	of
O	1209	1214	cases
O	1215	1216	(
B-iv-bin-abs	1216	1218	11
O	1218	1219	/
B-intervention-participants	1219	1221	59
O	1222	1224	in
O	1225	1228	the
O	1229	1234	INTRA
O	1235	1240	group
O	1241	1244	and
B-cv-bin-abs	1245	1247	16
O	1247	1248	/
B-control-participants	1248	1250	64
O	1251	1253	in
O	1254	1257	the
O	1258	1262	PERI
O	1263	1268	group
O	1268	1269	)
O	1269	1270	.

O	1271	1274	Our
O	1275	1280	study
O	1281	1286	found
O	1287	1289	no
O	1290	1303	statistically
O	1304	1315	significant
O	1316	1327	differences
O	1328	1330	in
O	1331	1334	the
O	1335	1344	detection
O	1345	1350	rates
O	1351	1353	of
O	1354	1362	axillary
O	1363	1365	or
O	1366	1371	extra
O	1371	1372	-
O	1372	1380	axillary
O	1381	1389	sentinel
O	1390	1395	lymph
O	1396	1401	nodes
O	1402	1409	between
O	1410	1413	the
O	1414	1417	two
O	1418	1424	groups
O	1424	1425	;
O	1426	1433	however
O	1433	1434	,
O	1435	1437	we
O	1438	1446	observed
O	1447	1454	greater
O	1455	1464	technical
O	1465	1473	efficacy
O	1474	1478	with
O	1479	1491	intratumoral
O	1492	1503	radiotracer
O	1504	1518	administration
O	1518	1519	.
